drugset / Trial / NCT02172248

Relative Bioavailability BI 10773 and Metformin in Healthy Male Volunteers

NCT02172248

Phase 1 Completed 16 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective was to investigate a possible drug-drug interaction between BI 10773 and metformin when co-administered as multiple oral doses. Therefore, the relative bioavailabilities of BI 10773 and metformin were determined when both drugs were given in combination compared with BI 10773 or metformin given alone.

Timeline

Start
2009-01
Primary completion
2009-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 50 mg Oral
Subject Metformin Small molecule 1000 mg Oral

Indications

No indication recorded.